Xilio Therapeutics, Inc. · Stock award · Stock Option (right to buy)

What does this filing report?

An SEC Form 4 filing for Xilio Therapeutics, Inc. records a stock award involving Stock Option (right to buy) on November 21, 2025. The reported quantity was 25,000. The filing date is November 25, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Derivative terms

Underlying security

Common Stock

Underlying quantity

25,000

Conversion / exercise price

1.5

Exercise date

Not reported

Expiration date

August 15, 2033

Filing footnotes & remarks

F1

On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 1 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025.

F2

The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.

F3

This option was granted on December 7, 2021 and vested on December 2, 2022 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through December 2, 2025.

F4

The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F5

This option was granted on November 1, 2022. The shares underlying the option began vesting on December 1, 2022 and continue to vest in equal monthly installments thereafter through November 1, 2026.

F6

This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027.

F7

Immediately exercisable.

F8

This option was granted on September 5, 2023. The shares underlying the option began vesting on October 1, 2023 and continue to vest in equal monthly installments thereafter through September 1, 2027.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.